Andrew Davis - 18 Nov 2024 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Reporting relationship: SVP, Chief Business Officer
Issuer ticker: IRWD
Reported as of: 18 Nov 2024
Net transaction value: -$21,869
SEC form: 4
Accepted by SEC: 20 Nov 2024, 16:05:04 UTC
Prior SEC filing: 22 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Brian Tessler, Attorney-in-Fact

Key filing fact

Andrew Davis filed Form 4 for IRONWOOD PHARMACEUTICALS INC (IRWD) on 20 Nov 2024.

Key facts

This page summarizes Andrew Davis's Form 4 filing for IRONWOOD PHARMACEUTICALS INC (IRWD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Nov 2024, 16:05.

Change

Previous filing in this sequence was filed on 22 May 2024.
Current net transaction value: -$21,869.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRWD transaction

Class A Common Stock

Sale

Transaction value: $21,869
Shares: -5,360
Change %: -1.8%
Price: $4.08
Shares after: 284,685
Date: 18 Nov 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person.

Footnote F2

The Reporting Person acquired 2,014 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2024.